News | Peripheral Artery Disease (PAD) | November 09, 2018

iDissection Classification Study to Evaluate Dissection Rate of Flex Dynamic Scoring Catheter

New study to determine if Flex Catheter reduces dissections and the need for bailout stents in peripheral arteries

iDissection Classification Study to Evaluate Dissection Rate of Flex Dynamic Scoring Catheter

November 9, 2018 — VentureMed Group Inc. announced the initiation of a new study to determine if the Flex Dynamic Scoring Catheter reduces dissections and the need for bailout stents in peripheral arteries. The study, entitled “Arterial Dissections Following FLEX Scoring and Adjunctive Balloon Angioplasty: Intravascular Ultrasound Assessment and Correlation with Angiographic Findings,” will utilize intravascular ultrasound (IVUS) to identify the health of the vessel after treatment.

Nicolas W. Shammas, M.D., founder and director of the Midwest Cardiovascular Research Foundation in Davenport, Iowa is the principal investigator for the study. This study is the second iDissection study performed by Shammas. The first study revealed that after atherectomy, in the peripheral arteries, significant dissections are more visible by a ratio of 6:1 when using IVUS in comparison to the typical angiogram. Deducing that the presence and severity of dissection after atherectomy may have been underestimated, especially for deeper dissections which are associated with recurrent restenosis, recoil and possibly acute closure.

“After the indicative results of the initial iDissection study, I am motivated to look for vessel prep devices that further reduce the need for provisional stenting,” said Shammas. “I am optimistic about the ability of the Flex Catheter to reduce the rate of high-grade dissections and looking forward to the evaluation.”

Using IVUS, the new study will evaluate the dissection rates of 15 patients following treatment of femoropopliteal denovo or no-stent restenosis by the Flex Dynamic Scoring Catheter and plain old balloon angioplasty (POBA).

VentureMed Group was an exhibitor at Vascular Interventional Advances (VIVA) in Las Vegas and the VEITH Symposium in New York during the month of November.

For more information: www.venturemedgroup.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now